ECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logo
  • Home
  • Archives
  • Contact
✕
  • Filter by
  • Categories
  • Tags
  • Authors
  • Show all
  • All
  • Acute lymphoblastic leukemia
  • Acute myeloid leukemia
  • Adolescents and young adults
  • Advocacy
  • Anal cancer
  • Antioxidants
  • AYA
  • Bladder cancer
  • Blood cancers
  • Brain cancer
  • Breast cancer
  • Cancer care delivery
  • Caregiving
  • Chemotherapy
  • Chronic lymphocytic leukemia
  • Colorectal cancer
  • ComboMATCH
  • Communication
  • COVID-19
  • DCIS
  • De-escalation
  • Esophagus cancer
  • Financial hardship
  • Gallbladder cancer
  • Gastroesophageal cancer
  • Geriatric oncology
  • GI cancer
  • Green tea
  • HAI chemotherapy
  • Head and neck cancer
  • Head and neck squamous cell carcinoma
  • Health equity
  • Hepatic arterial infusion chemotherapy.
  • HER2+ breast cancer
  • Hormone therapy
  • Imaging
  • Immune system therapy
  • Immunotherapy
  • Implementation science
  • In memory
  • Kidney cancer
  • Language
  • Late Effects
  • Leiomyosarcoma
  • Leukemia
  • LGBTQ+
  • Liver cancer
  • Lung cancer
  • Lymphoma
  • Mammography
  • Mantle cell lymphoma
  • Melanoma
  • Men's health
  • Mesothelioma
  • Minimal residual disease
  • MRI
  • Multiple myeloma
  • Myelodysplastic syndrome
  • Myeloma
  • National Clinical Trials Network
  • NCI-MATCH
  • Neuropathy
  • Non-Hodgkin lymphoma
  • Non-small cell lung cancer
  • Nose and sinus cancer
  • Older adults
  • Pancreatic cancer
  • Pancreatic cysts
  • Patient advocacy
  • Patient care
  • Patient education
  • Patient navigation
  • Patient-reported outcomes
  • Penile cancer
  • Peripheral T-cell lymphoma
  • Personalized medicine
  • Personalized screening
  • Personalized treatment
  • Precision medicine
  • Prevention
  • Prostate cancer
  • Radiation therapy
  • Rare cancer
  • Rare cancers
  • Real-world data
  • Real-world evidence
  • Registry studies
  • Renal cell carcinoma
  • Research results
  • Sarcoma
  • Screening
  • Sexual and gender minorities
  • Side effects
  • Skin cancer
  • Smoldering multiple myeloma
  • Social genomics
  • Soft tissue sarcoma
  • Solid tumors
  • Squamous cell carcinoma
  • Surveillance
  • Survivorship
  • Symptom management
  • Symptom science
  • Targeted therapy
  • Throat cancer
  • Thyroid cancer
  • Trial results
  • Triple-negative breast cancer
  • Tumor test
  • Upper tract urothelial cancer
  • Urothelial cancer
February 9, 2020
green awareness ribbon hope
February 9, 2020
Categories
  • New Trials

Now Enrolling: Trial EA4181 is comparing three different chemotherapy treatments for newly diagnosed mantle cell lymphoma

Right now, researchers do not know the ideal treatment for people with newly diagnosed mantle cell lymphoma.
Do you like it?
0 Read more
October 14, 2019
October 14, 2019
Categories
  • New Trials

Now Enrolling: Trial EAZ171 is addressing an important survivorship issue…neuropathy in African American women with breast cancer

Recently Activated: Trial EAZ171 is addressing an important survivorship issue...neuropathy in African American women with breast cancer.
Do you like it?
0 Read more
Prev page
1234567

Office of Communications
1818 Market Street, Suite 3000
Philadelphia, PA 19103
Phone: 215.789.3631
www.ecog-acrin.org

Contact us with any questions

© 2019-2025 ECOG-ACRIN Cancer Research Group. All Rights Reserved. Designed by Create & Associates, Inc